Traveler's joy

Traveller's Joy (Clematis vitalba L.): A Comprehensive Reference

1. Identity and Botanical Profile

Scientific and Common Names

Traveller's Joy is the common English name for the climbing plant formally designated Clematis vitalba L. The generic name Clematis is derived from the Greek word klema, meaning "a vine branch," alluding to its vine-like twining climbing habit, while the Latin specific epithet vitalba translates as "the white vine," referring to the wild species. In the late sixteenth century, the English botanist John Gerard walked along the chalky hedgerows of southern England and observed a wild, scrambling vine covered in feathery white seed heads, and in his famous 1597 publication The Herball, he gave the plant the name "Traveller's Joy," noting that it draped itself over bushes and fences along country highways, offering a beautiful sight to weary people making long journeys on foot or horseback. Gerard is also quoted as describing the plant as "esteemed for pleasure by reason of the goodly shadow and the pleasant sent or savour of its flowers," and giving his reason for the name: "because of its decking and adorning waies and hedges where people travel."

There are a large number of English common names in existence — Grigson (1955, 1987) lists 36 — but "Travellers' Joy" was coined by John Gerard for his 1597 English herbal. The most widespread alternative English common name is Old Man's Beard, a reference to the silvery-white twist of long, feathery styles that adorn the fruit achenes. Other synonyms include Wild Clematis and Virgin's Bower. Taxonomic synonyms documented in the literature include Anemone vitalba, Clematis bellojocensis, Clematis scandens, and Clematis sepium, among others.

Taxonomy and Botanical Description

Clematis vitalba belongs to the Ranunculaceae family, which encompasses a diverse array of flowering plants. The genus Clematis is a cosmopolitan, temperate northern hemisphere genus comprising 200–300 species, most of which are woody climbers, although some are non-climbing shrubs. Native to Europe, North Africa, and parts of Asia, this vigorous climbing vine is characterized by its woody stems, compound leaves, and fragrant flowers. The native range of C. vitalba extends through Europe into North Africa and western Asia; it is native to the southern part of Britain but has been widely introduced and naturalised as far north as central Scotland, and is also widely naturalised globally in temperate regions, where it may become a serious invasive species.

The leaves of Clematis vitalba are arranged in an opposite fashion on ridged stems, and each leaf comprises three to five leaflets. The plant flowers from July to September, producing small, fragrant, creamy-white flowers, and forms characteristic fruits — dry achenes covered in long, persistent, silvery-white styles that give rise to the "Old Man's Beard" common name. The internal structures of Clematis stems have often been examined microscopically; C. vitalba indeed has a high proportion of its stem as large-diameter vessels, explaining its extraordinary water-conducting capacity and high growth rate. Like all lianas, it does not need much woody tissue for mechanical support, as it leans and twists on other plants for support. It is a deciduous climber growing to 15 m (49 ft) in length.

Common Preparation Forms

Clematis vitalba enters commerce and traditional practice in several distinct forms:

• Dried aerial parts / ethanol extracts: The dried aerial parts (leaves, stems, flowering tops) have been the principal material studied in preclinical pharmacological research, most commonly as ethanol or methanol extracts.
• Poultices and topical preparations: Traditionally, the leaves and stems were employed as topical remedies to ease joint pain, rheumatism, and skin irritations; poultices made from Clematis vitalba were often applied to affected areas to reduce inflammation and promote healing.
• Homeopathic liquid preparations: In the homeopathic pharmacopoeia, the commercially marketed Bach Original Flower Remedies Clematis preparation lists its active ingredient as a 5× dilution of Clematis vitalba HPUS, with 27% alcohol as the inactive ingredient.
• Homeopathic pellets: Homeopathic Clematis vitalba remedies are also available as lactose-free pellets, oral drops, and medicating potency preparations.
• Traditional infusion / decoction: Ethnopharmacological data mention the use of flowers and leaves as an infusion for wounds (external use) and respiratory disorders.
• Edible preparations (food use): In parts of central and southern Italy, the young shoots of this species are boiled before being mixed with eggs and/or cheese and fried, used in a traditional frittata (an omelette of vegetables and beaten eggs).

2. Traditional and Historical Use

Classical Antiquity and Early Modern Europe

The plant probably comes from Europe and has been used for medicinal purposes since ancient times. Pliny and Dioscorides make mention of the clematis, although there is some controversy regarding the true botanical parentage of the plants cited by these classical authors. Already in ancient times, Dioscorides and other authors recommended different parts of the plant for various ailments, from rheumatism to dysentery. The leaves of the plant mixed with wine were used to combat various digestive problems, diarrhea, and tooth pain, and were ascribed some benefit against snake bites.

During the Roman Imperial period, Columella in the De Re Rustica (Agriculture) wrote that, during the spring equinox, young shoots of asparagus, Ruscus sp., Clematis sp., and black briony were picked and pickled along with aromatic herbs and then eaten; in Latium and other Italian regions, the habit of gathering and boiling these shoots still exists today, with boiling important because plants like Clematis vitalba are toxic if consumed raw. The use of the young boiled shoots of Clematis vitalba in salads in Tuscany (Lucca district) is documented as very ancient, already known since the 17th century.

The French common name herbe aux gueux ("beggar's plant") originated from the use by beggars in Paris of the acrid juice of the plant to produce ulcerous wounds as a means of exciting pity. This reflects knowledge of the plant's powerful counter-irritant properties, deliberately exploited in historical contexts.

European Folk Medicine

Traveller's Joy has a long tradition of use in European folk medicine. Historically, extracts from this vining plant were used to address a variety of ailments, particularly those related to pain and inflammation, such as rheumatism and joint discomfort. The plant's aerial parts were sometimes incorporated into poultices or topical applications, and it has also appeared in homeopathic remedies.

Internally, the tincture has been used to treat urethral stricture and decoctions against cough; externally, it has been used as a wound-healing agent and against skin inflammation. Traveller's Joy has been used in various treatments for its purported anti-inflammatory properties; traditional recipes used the plant to treat various ailments, including skin irritations and stress.

Anatolian and Lebanese Traditional Medicine

The aerial parts of various Clematis species are particularly used in Europe and Eastern Asia as a remedy to reduce pain and fever, as a diuretic, and in the treatment of rheumatic pain, eye infections, gonorrhoeal symptoms, bone illnesses, chronic skin disorders, gout, and varicosity. The most salient application related to folkloric usage is found in the treatment of rheumatic ailments. In Northern Anatolia, Clematis cirrhosa and Clematis flammula leaves or aerial parts are used to provide temporary relief of joint pains; ground fresh aerial part or leaves are applied on inflammatory joints for about 15–30 minutes. The ensuing irritation on the skin opens a gap and drains the edema, and in some cases, the wound is plugged to provide continuous drainage for 20–25 days. Moreover, Clematis vitalba branches have also been used to stop tooth pain by smoking like a cigarette in northwestern Anatolia.

Different species of the genus Clematis from the Ranunculaceae family, rich in the glycoside ranunculin, are used in traditional Lebanese medicine, including Clematis flammula L. (virgin's bower), Clematis cirrhosa L. (fern-leaved clematis), and Clematis vitalba L. Topical use of leaf juice is traditionally utilised in Italy and other areas for abdominal pains, flu, bronchitis, intestinal disorders, inflammation, skin irritation, infections, and for wound treatment.

Italian Ethnobotany and Food Use

C. vitalba L. is consumed as food in Italy. The development stage is an important factor in affecting toxicity; young shoots of Clematis vitalba are preferred to more mature ones because they contain lower levels of toxic components. Heat is another effective way to reduce toxicity; the species is among those that were solely consumed cooked. Young shoots can be cooked and used like hop shoots (Humulus lupulus), caution being advised due to reports of toxicity. The leaves are boiled then used in stews and as a spice. The young sprouts are eaten, and the young shoots are also pickled and used in omelettes.

Bach Flower System (20th Century)

Clematis vitalba is one of the 38 remedies in the system of Bach flower remedies developed by Dr. Edward Bach, a system that captures the essence of flowers, each one corresponding to a different emotional state to support everyday wellness. In homeopathic preparations, highly diluted tinctures derived from the plant address rheumatism and eruptions, while it appears in Bach flower remedies for emotional states described as indecision or dreaminess. It is important to note that the Bach Original Flower Remedies product carrying a homeopathic disclaimer states it has not been evaluated by the Food and Drug Administration for safety or efficacy, and the FDA is not aware of scientific evidence to support homeopathy as effective.

3. Key Constituents and Active Compounds

Major Phytochemical Classes

Clematis vitalba contains protoanemonin, anemonin, terpenoids, saponins (vitalboside A, vitalboside F, vitalboside D, vitalboside G, vitalboside H), alkaloids, sterols (β-sitosterol, campesterol), phenolic acids (caffeic and chlorogenic acids), and flavonoids (vitaboside).

A survey of the literature revealed that triterpene saponins, alkaloids, flavonoids, lignans, steroids, coumarins, macrocyclic compounds, phenolic glycosides, anemonin, and volatile oils constitute the major classes of chemical constituents in the genus Clematis. The genus is particularly rich in active components such as pentacyclic triterpenoid saponins (used traditionally in Chinese medicine), coumarins, flavonoids, and alkaloids.

Ranunculin–Protoanemonin–Anemonin Cascade

The most toxicologically and pharmacologically significant chemical pathway in C. vitalba is the conversion of a stable glucoside precursor into reactive irritant compounds. Ranunculin, a glucoside, serves as a chemotaxonomic marker in Ranunculaceae plants. When these plants are damaged, the enzyme β-glucosidase triggers the conversion of ranunculin into protoanemonin through hydrolysis; subsequently, protoanemonin undergoes cyclodimerization to form anemonin. Protoanemonin is liberated enzymatically from the glucosidic precursor ranunculin and can polymerize to anemonin. These three compounds have cytotoxic effects against tumour cell lines of the NCI 60 tumour panel. Anemonin has anti-inflammatory effects through inhibition of iNOS-mediated NO signalling elicited by LPS stimulation.

The primary toxic compound in Clematis species is ranunculin, a glycosidic precursor. When fresh plant material is chewed, crushed, or damaged, enzymes are released that convert ranunculin into protoanemonin — a vesicant that causes blistering and irritation upon contact with skin and mucous membranes, and is responsible for most of the acute adverse effects observed with Clematis. The concentration of protoanemonin is highest in fresh leaves and sap, and its irritating properties tend to diminish as the plant dries.

Saponins (Vitalbosides)

Pentacyclic triterpenoid saponins represent a dominant class of bioactive metabolites in C. vitalba, including aglycones such as caulosapogenin, linked to anti-inflammatory, analgesic, and hemolytic effects in traditional and pharmacological contexts. The named vitalbosides (A, D, F, G, H) are among the most studied individual saponin constituents isolated from this species. A fractionated analysis allowed the isolation of vitalboside as the principal agent of anti-inflammatory and antinociceptive effects in both subacute and chronic models.

Flavonoids and Phenolic Acids

Flavonoids reported from Clematis species include mainly apigenin, kaempferol, luteolin, and quercetin. Lignans from Clematis species are mainly eupomatene lignans, cyclolignans, monoepoxylignans, bisepoxylignans, and lignanolides, with C. vitalba among the species from which these have been reported. Phenolic acids caffeic and chlorogenic acid have also been identified in C. vitalba extracts.

Anemonin as an iNOS Inhibitor

The root contains the compound anemonin, which has been shown to have antibacterial, analgesic, sedative, and antispasmodic actions. Research on the related compound across Clematis species has shown that anemonin from Clematis crassifolia acts as a potent and selective inducible nitric oxide synthase (iNOS) inhibitor, as reported in the Journal of Ethnopharmacology. This mechanism — inhibition of iNOS-mediated nitric oxide production — is considered one of the key molecular pathways underlying the anti-inflammatory activity demonstrated in preclinical studies.

4. Scientific Evidence by Area of Use

4.1 Anti-inflammatory Activity

The most substantial body of preclinical evidence for C. vitalba concerns anti-inflammatory activity. The key experimental study is that of Yeşilada and Küpeli (2007), published in the Journal of Ethnopharmacology (vol. 110, pp. 504–515). Extracts obtained from the dried aerial parts of Clematis species are used as folk remedies worldwide for the treatment of various inflammatory ailments such as rheumatism and fever reduction; to test their effectiveness, extracts, fractions, and subfractions from dried Clematis vitalba aerial parts were studied in mice.

The ethanol extract from aerial parts showed significant in vivo (animal models) anti-inflammatory, antinociceptive (analgesic), and antipyretic effects in a dose-dependent manner; the anti-inflammatory effect may be due to the prostaglandin inhibition by vitalboside. Specifically, ethanol extracts of dried aerial parts demonstrated anti-inflammatory effects by inhibiting paw edema in rats (comparable to indomethacin at 100–200 mg/kg doses), antinociceptive activity in acetic acid-induced writhing and hot plate tests, and antipyretic reduction of yeast-induced hyperthermia.

Vitalboside exerted a potent and dose-dependent anti-inflammatory effect on carrageenan-induced paw edema; additionally, antipyretic and antinociceptive effects were noted with vitalboside. The ethanol extract also showed beneficial effects as an adjuvant in arthritis models.

Evidence strength: All available evidence for anti-inflammatory activity in C. vitalba is preclinical, based on in vivo animal models (mice and rats) and in vitro assays. Although few experimental studies have validated traditional claims, they employed uncharacterized crude extracts; such Clematis species need to be explored properly following bioactivity-directed fractionation to isolate bioactive constituents and evaluate their possible modes of action. No human clinical trials of C. vitalba extracts for anti-inflammatory conditions have been published.

4.2 Antinociceptive (Analgesic) Activity

Extracts of the aerial parts of the plant show a remarkable anti-inflammatory effect in the experimental model of carrageenan-induced edema and vascular permeability induced by acetic acid. A fractionated analysis allowed isolation of vitalboside as the principal agent of this antinociceptive effect, with antipyretic effects of the substance also proven.

Evidence strength: Preclinical only (murine models). No human data exist specifically for C. vitalba as an analgesic agent. Results from animal studies cannot be directly extrapolated to clinical efficacy in humans without further investigation.

4.3 Antimicrobial and Antifungal Activity

A broad activity against pathogenic yeast and yeast-like microorganisms was shown in crude extracts of young shoots of Clematis vitalba; minimum inhibitory concentrations (MICs) ranging from 1.4 to 12.3 μg/mL were observed. After fractionating with petroleum ether, ethyl acetate, and methanol, antimycotic activity was observed only in methanol fractions.

Methanol extracts of C. vitalba shoots exhibit a broad antifungal and antibacterial activity (MIC 1.6–12.3 µg/mL) as shown using the agar diffusion assay. Extracts from the young shoots showed antimicrobial activity against several yeast and yeast-like microorganisms, especially against several Prototheca species.

Evidence strength: In vitro only (agar diffusion and broth dilution assays). These are laboratory findings that have not been extended to in vivo infection models or human clinical studies.

4.4 Cytotoxic and Anticancer Activity

Protoanemonin, liberated enzymatically from its glucosidic precursor ranunculin, and its dimer anemonin have demonstrated cytotoxic effects against tumour cell lines of the NCI 60 tumour panel. Preliminary anticancer activity studies have been carried out on crude extracts of 26 traditionally used and medicinally promising species of the Clematis genus.

Evidence strength: Although few experimental studies have validated traditional claims, uncharacterized crude extracts were employed in most of the activities. No clinical evidence exists for anticancer properties of C. vitalba. In vitro cytotoxicity data cannot be taken as evidence of anticancer efficacy in humans.

4.5 Antioxidant Activity

Flavonoid and phenolic acid content has led researchers to assess antioxidant capacity in Clematis species. These constituents have drawn interest for their antioxidant and anti-inflammatory properties; preclinical research, including in vitro and animal studies, has provided some evidence that extracts from Traveller's Joy may help modulate inflammatory pathways and protect cells from oxidative stress.

Evidence strength: Preliminary; the specific antioxidant activity data derive largely from in vitro assays on related Clematis species. No clinical antioxidant outcome data are available for C. vitalba.

4.6 Homeopathic Use — Clinical Evidence

In the homeopathic tradition, C. vitalba is prescribed for conditions including rheumatic pain, urinary complaints, and skin eruptions. In homeopathic preparations, highly diluted tinctures derived from the plant are used to address rheumatism and eruptions, and the plant appears in Bach flower remedies for emotional states such as indecision; however, clinical evidence in humans is lacking and efficacy remains unproven beyond preliminary studies.

No clinical evidence supports dosage recommendations for clematis. The FDA has stated that it is not aware of scientific evidence to support homeopathy as effective, as noted on the product's own labelling.

5. Body Systems and Health Areas Associated with Clematis vitalba

Based on the totality of traditional use and preclinical research documented in the sources above, the following body systems and health areas have been associated with C. vitalba:

• Musculoskeletal and joint health: Aerial parts of Clematis species are used in Europe and Eastern Asia as a remedy for rheumatic pain, bone illnesses, and gout.
• Nervous system / pain perception: Anemonin, present in the roots, has been shown to have analgesic, sedative, and antispasmodic actions.
• Immune and inflammatory response: The genus is used in folk medicine for the treatment of asthma, rheumatism, and nervous disorders, and has demonstrated antibacterial, anti-inflammatory, analgesic, and anticancer effects in preclinical studies.
• Urinary tract: Internally, the tincture has been used to treat urethral stricture. It has also been used as a diuretic in European and Eastern Asian traditions.
• Skin and integumentary system: The leaves and stems were employed as topical remedies to ease skin irritations; poultices were applied to affected areas to reduce inflammation and promote healing.
• Antimicrobial defence: Crude extracts from young shoots have exhibited antimicrobial effects against pathogenic yeasts and yeast-like fungi, including Candida species, with minimum inhibitory concentrations ranging from 0.5 to 4 mg/mL.
• Febrile states (antipyresis): Vitalboside, isolated from C. vitalba, has demonstrated antipyretic effects in addition to its anti-inflammatory and antinociceptive actions.

6. Dosage Forms and Dosages Reported in Studies

There is no validated clinical dosage for Clematis vitalba preparations; all dosage data in the pharmacological literature derive from preclinical animal experiments or from marketed homeopathic product labelling. The following dosage figures are reproduced strictly as stated in their respective sources:

• Preclinical anti-inflammatory studies (animal model): For comparative reference, Clematis brachiata (a related species) exerted anti-inflammatory effects at doses of 100, 200, and 400 mg/kg on carrageenan-induced paw edema in rats, with the 400 mg/kg dose being the most potent. Ethanol extracts of dried C. vitalba aerial parts demonstrated anti-inflammatory effects comparable to indomethacin at 100–200 mg/kg doses in rodent paw-edema models.
• Bach Flower Remedy (homeopathic liquid): The commercially marketed product directs taking 2 drops in the mouth or in water, sipping at intervals, and repeating as needed. The active ingredient is listed as a 5× dilution of Clematis vitalba HPUS.
• Homeopathic pellets: Some homeopathic pellet preparations are formulated at potencies including Flos 6X, 30C, and 200C.

No clinical evidence supports dosage recommendations for clematis. All animal study dosages above are expressed in mg/kg body weight and are not directly applicable to human supplementation.

7. Safety Considerations

Primary Toxic Principle: Protoanemonin

The primary toxic compound in Clematis species is ranunculin, a glycosidic precursor. When fresh plant material is chewed, crushed, or damaged, enzymes are released that convert ranunculin into protoanemonin — a vesicant that causes blistering and irritation upon contact with skin and mucous membranes, responsible for most of the acute adverse effects observed with Clematis.

Protoanemonin is an irritant oil glycoside that is not readily absorbed from the gastrointestinal tract or metabolized in it, with the result that irritation is likely to occur in the oral cavity and throughout the gastrointestinal tract.

Irritant Effects upon Contact (Topical)

Extended skin contact with the freshly harvested, bruised plant can lead to treatment-resistant blisters and cauterizations due to the release of protoanemonin, which is severely irritating to skin and mucous membranes. If taken internally, severe irritation to the gastrointestinal tract, combined with colic, diarrhea, and irritation of the urinary drainage passages, are possible. This severe reaction is what traditional practitioners sometimes sought to elicit as a counter-irritation therapy.

Symptoms of Ingestion

Chewing releases protoanemonin, causing burning of the mouth and mucous membranes, salivation, abdominal pain and cramping, nausea, and vomiting. Hematuria and renal function effects have also been described. Inadvertent exposure and exposure in animals is often self-limited by the oral symptoms.

Effect of Heat and Drying

Because protoanemonin is present mainly in fresh plant material, cooking or drying results in its decomposition. All parts of the plant are poisonous, but the toxic principle is dissipated by heat or by drying. The concentration of protoanemonin is highest in the fresh leaves and sap, and its irritating properties tend to diminish as the plant dries. This explains why boiled young shoots have been safely consumed as a food in Italy.

Fatality Risk and Overdose Management

Fatalities are not common, probably due to the rapid and intense acrid taste and irritation resulting from oral contact. If a large amount has been accidentally ingested, gastric lavage is recommended, followed by demulcents to soothe irritated membranes. Overdose is treated with gastric lavage followed by activated charcoal. Death by asphyxiation following the intake of large quantities of protoanemonin-forming plants has been observed in animal experiments; however, the toxicity of C. vitalba is less than that of many other Ranunculaceae (such as Anemone nemorosa) due to the relatively low levels of protoanemonin-forming agents.

Regulatory and Evidence Status

Today, medicinal use of Clematis vitalba is generally not recommended due to the toxicity of its sap and the irritating effects on the skin and mucous membranes. While fresh Clematis vitalba aerial parts have long been considered toxic and the plant is well known to be a revulsive and a skin irritant because of its protoanemonin content, its extracts have shown anti-inflammatory, anti-nociceptive, antipyretic, antimicrobial, and anti-obesity effects in preclinical studies. Modern scientific research on Clematis vitalba is still in its early stages.

Formal contraindications for Clematis vitalba preparations have not been systematically identified in the scientific literature. However, the well-documented toxicity of the raw plant makes unsupervised self-administration of unprocessed material inadvisable.

References

• Yeşilada E, Küpeli E. "Clematis vitalba L. aerial part exhibits potent anti-inflammatory, antinociceptive and antipyretic effects." Journal of Ethnopharmacology, 2007;110(3):504–515. ScienceDirect.
• Chawla A, Kumar A, Sharma A. "The genus Clematis (Ranunculaceae): Chemical and pharmacological perspectives." Journal of Ethnopharmacology, 2012. ScienceDirect.
• Clematis Vitalba — an overview. ScienceDirect Topics.
• Clematis — an overview. ScienceDirect Topics.
• Buzzini P, Pieroni A. "Antimicrobial activity of extracts of Clematis vitalba towards pathogenic yeast and yeast-like microorganisms." Fitoterapia, 2003. ScienceDirect.
• ResearchGate: "The genus Clematis (Ranunculaceae): Chemical and pharmacological perspectives."
• ResearchGate: "Clematis vitalba L. aerial part exhibits potent anti-inflammatory, antinociceptive and antipyretic effects."
• Jin F, Narkowicz C, Jacobson GA. "Protoanemonin Content Variation between Clematis spp.: Leaf, Stem and Root." Natural Product Communications, 2013.
• Bentham Science: "Ranunculin, Protoanemonin, and Anemonin: Pharmacological and Chemical Perspectives." Current Medicinal Chemistry, 2024.
• Oxford University Plants 400: Clematis vitalba.
• Woodland Trust: Traveller's Joy (Clematis vitalba).
• BSBI: Clematis vitalba L. (Traveller's-joy).
• Trees and Shrubs Online: Clematis vitalba.
• Botany in Scotland: Traveller's Joy, aka Old Man's Beard (Clematis vitalba).
• Drugs.com Natural Product Database: Clematis — Uses, Benefits & Dosage.
• DailyMed (NLM/NIH): Bach Original Flower Remedies — Clematis vitalba solution label.
• DailyMed (NLM/NIH): Bio Clematis — Clematis vitalba flower liquid label.
• Pieroni A et al. "Wild food plants used in traditional vegetable mixtures in Italy." Journal of Ethnopharmacology, 2016. ScienceDirect.
• PMC/NIH: "The Renaissance of Wild Food Plants: Insights from Tuscany (Italy)." PMC8834290.
• Journal of Ethnobiology and Ethnomedicine (Springer): "The wild taxa utilised as vegetables in Sicily (Italy): a traditional component of the Mediterranean diet."
• IJNRD: "Bioactive Saponins from Clematis — Mini Review."
• PMC/NIH: "Insights into Clematis cirrhosa L. Ethanol Extract: Cytotoxic Effects, LC-ESI-QTOF-MS/MS Chemical Profiling, Molecular Docking, and Acute Toxicity Study." PMC11510288.
• Plants For A Future (PFAF): Clematis vitalba — Traveller's Joy.
• ACEP Now (American College of Emergency Physicians): "Toxicology Answer: What Are the Side Effects of Chewing This Beautiful Bloom?"
• E-flora BC / PDR Reference: Clematis Sp. — Botanical, toxicological notes.